Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 17/20 | 0.65 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11343920 | 0.93 | IGF1R (0.77) | IGF1RJAK3JAK2TBK1 | |
| SCHEMBL14050601 | 0.86 | IGF1R (0.62) | IGF1R | |
| SCHEMBL11342893 | 0.84 | IGF1R (0.75) | IGF1R | |
| SCHEMBL4459249 | 0.82 | IGF1R (0.76) | IGF1RTBK1 | |
| SCHEMBL12438498 | 0.81 | IGF1R (0.63) | IGF1RTBK1 | |
| SCHEMBL11345387 | 0.81 | IGF1R (0.75) | IGF1RJAK2 | |
| SCHEMBL4454928 | 0.80 | IGF1R (0.78) | IGF1RTBK1 | |
| SCHEMBL11342847 | 0.80 | IGF1R (0.74) | IGF1RTBK1 | |
| SCHEMBL4558159 | 0.79 | IGF1R (0.78) | IGF1RTBK1 | |
| SCHEMBL11938447 | 0.78 | IGF1R (0.56) | IGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841760-B1 | PYRIMIDINE DERIVATIVES AS KINASE MODULATORS AND METHOD OF USE | EXELIXIS INC (US) | 2011-08-10 | — | — | EP | disclosed |
| WO-2008127594-A2 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF PI3K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |